Pancreatic cancer stroma: an update on therapeutic targeting strategies

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · see citing works

Tumor angiogenesis: therapeutic implications

Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · see citing works

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · see citing works

Pancreatic Cancer

Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202 · see citing works

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · see citing works

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · see citing works

Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · see citing works

Remodelling the extracellular matrix in development and disease

Bonnans, C., Chou, J., & Werb, Z. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3904 · Cited by 4,367 · see citing works

The biology and function of fibroblasts in cancer

Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366 · see citing works

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,019 · see citing works

Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion

Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759 · see citing works

Integrins in cancer: biological implications and therapeutic opportunities

Desgrosellier, J. S., & Cheresh, D. A. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2748 · Cited by 3,721 · see citing works

Genomic analyses identify molecular subtypes of pancreatic cancer

Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · see citing works

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis

Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206 · see citing works

Hepatogastroenterology

Chen, L., Li, N., & Ye, H. (2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,199 · see citing works

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874 · see citing works

Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children

Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824 · see citing works

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival

Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681 · see citing works

Transplacental Carcinogenesis by Stilbestrol

Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640 · see citing works

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · see citing works

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer

Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., Corbo, V., Oni, T. E., Hearn, S. A., Lee, E. J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162024 · Cited by 2,590 · see citing works

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

Pàez‐Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,344 · see citing works

Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer

Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302 · see citing works

Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts

Elyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A., Teinor, J. A., Belleau, P., Biffi, G., Lucito, M. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0094 · Cited by 2,241 · see citing works

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · see citing works

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194 · see citing works

Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy

Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · see citing works

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · see citing works

Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma

Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085 · see citing works

Integrated genomic characterization of pancreatic ductal adenocarcinoma

Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019 · see citing works

Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer

Zheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J. A., Sugimoto, H., Wu, C.-C., LeBleu, V. S., & Kalluri, R. (2015) · Nature · doi:10.1038/nature16064 · Cited by 2,018 · see citing works

30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology

Zhang, Q., Lenardo, M. J., & Baltimore, D. (2017) · Cell · doi:10.1016/j.cell.2016.12.012 · Cited by 1,979 · see citing works

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977 · see citing works

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967 · see citing works

Pancreatic cancer

Li, D., Xie, K., Wolff, R. A., & Abbruzzese, J. L. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15841-8 · Cited by 1,715 · see citing works

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

Ebos, J. M. L., Lee, C. R., Cruz‐Muñoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,710 · see citing works

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611 · see citing works

Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner

Erez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515 · see citing works

Defective TCR expression in transgenic mice constructed using cDNA‐based α‐ and β‐chain genes under the control of heterologous regulatory elements

Barnden, M., Allison, J., Heath, W. R., & Carbone, F. (1998) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.1998.00709.x · Cited by 1,491 · see citing works

IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma

Biffi, G., Oni, T. E., Spielman, B., Hao, Y., Elyada, E., Park, Y., Preall, J., & Tuveson, D. A. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0710 · Cited by 1,360 · see citing works

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311 · see citing works

Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy

Sherman, M. H., Yu, R. T., Engle, D. D., Ding, N., Atkins, A. R., Tiriac, H., Collisson, E. A., Connor, F., Van Dyke, T., Kozlov, S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.007 · Cited by 1,158 · see citing works

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120 · see citing works

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099 · see citing works

Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression

Hwang, R. F., Moore, T. T., Arumugam, T., Ramachandran, V., Amos, K. D., Rivera, A. M., Ji, B., Evans, D. B., & Logsdon, C. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5714 · Cited by 1,093 · see citing works

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E. M., Burkhart, R. A., Denroche, R. E., Jang, G.-H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0349 · Cited by 1,092 · see citing works

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

Jiang, H., Hegde, S., Knolhoff, B. L., Zhu, Y., Herndon, J. M., Meyer, M. A., Nywening, T. M., Hawkins, W. G., Shapiro, I. M., Weaver, D. T., et al. (2016) · Nature Medicine · doi:10.1038/nm.4123 · Cited by 1,060 · see citing works

Bone Marrow-Derived Myofibroblasts Contribute to the Mesenchymal Stem Cell Niche and Promote Tumor Growth

Quante, M., Tu, S. P., Tomita, H., Gonda, T. A., Wang, S. S. W., Takashi, S., Baik, G. H., Shibata, W., DiPrete, B. L., Betz, K. S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.020 · Cited by 1,047 · see citing works

Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer

Bayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947 · see citing works

Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein

Kamphorst, J. J., Nofal, M., Commisso, C., Hackett, S. R., Lu, W., Grabocka, E., Vander Heiden, M. G., Miller, G., Drebin, J. A., Bar-Sagi, D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2211 · Cited by 893 · see citing works

Single-cell RNA sequencing reveals stromal evolution into LRRC15(+) myofibroblasts as a determinant of patient response to cancer immunotherapy

Dominguez, C. X., Müller, S., Keerthivasan, S., Koeppen, H., Hung, J., Gierke, S., Breart, B., Foreman, O., Bainbridge, T. W., Castiglioni, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0644 · Cited by 857 · see citing works

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

Kindler, H. L., Niedzwiecki, D., Hollis, D. R., Sutherland, S., Schrag, D., Hurwitz, H. I., Innocenti, F., Mulcahy, M. F., O'Reilly, E. M., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 848 · see citing works

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., et al. (2017) · Nature · doi:10.1038/nature21724 · Cited by 841 · see citing works

Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression

Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807 · see citing works

A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells

Barsoum, I. B., Smallwood, C. A., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0992 · Cited by 767 · see citing works

Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors

Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733 · see citing works

Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia

Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.024 · Cited by 721 · see citing works

EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration

Aiello, N. M., Maddipati, R., Norgard, R. J., Balli, D., Li, J., Yuan, S., Yamazoe, T., Black, T. A., Sahmoud, A., Furth, E. E., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.05.027 · Cited by 708 · see citing works

The pancreatic stellate cell: a star on the rise in pancreatic diseases

Omary, M. B., Lugea, A., Lowe, A. W., & Pandol, S. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30082 · Cited by 693 · see citing works

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

Shrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677 · see citing works

Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia

Conley, S. J., Gheordunescu, E., Kakarala, P., Newman, B., Korkaya, H., Heath, A. N., Clouthier, S. G., & Wicha, M. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018866109 · Cited by 663 · see citing works

Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells

Bachem, M. G., Schünemann, M., Ramadani, M., Siech, M., Beger, H. G., Buck, A. K., Zhou, S., Schmid‐Kotsas, A., & Adler, G. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.036 · Cited by 659 · see citing works

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

Cutsem, E. V., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Laethem, J. V., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J. G. C. E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0238 · Cited by 651 · see citing works

Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer

Whatcott, C. J., Diep, C. H., Jiang, P., Watanabe, A. T., Lobello, J. R., Chao Sima, A., Hostetter, G. H., Shepard, H. M., Hoff, D. D. V., & Han, H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1051 · Cited by 646 · see citing works

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

Hu‐Lowe, D. D., Zou, H. Y., Grazzini, M. L., Hallin, M. E., Wickman, G., Amundson, K., Chen, J. H., Rewolinski, D. A., Yamazaki, S., Wu, X., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0652 · Cited by 640 · see citing works

Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression

Seino, T., Kawasaki, S., Shimokawa, M., Tamagawa, H., Toshimitsu, K., Fujii, M., Ohta, Y., Matano, M., Nanki, K., Kawasaki, K., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2017.12.009 · Cited by 631 · see citing works

Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity.

Casazza, A., Laoui, D., Wenes, M., Rizzolio, S., Bassani, N., Mambretti, M., Deschoemaeker, S., Ginderachter, J. V. V., Tamagnone, L., & Mazzone, M. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.007 · Cited by 601 · see citing works

Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression

Laklai, H., Miroshnikova, Y. A., Pickup, M. W., Collisson, E. A., Kim, G., Barrett, A., Hill, R. C., Lakins, J. N., Schlaepfer, D. D., Mouw, J. K., et al. (2016) · Nature Medicine · doi:10.1038/nm.4082 · Cited by 598 · see citing works

Desmoplastic Reaction in Pancreatic Cancer: Role of Pancreatic Stellate Cells

Apte, M. V., Park, S., Phillips, P. A., Santucci, N., Goldstein, D., Kumar, R. K., Ramm, G. A., Buchler, M., Friess, H., McCarroll, J. A., et al. (2004) · Pancreas · doi:10.1097/00006676-200410000-00002 · Cited by 591 · see citing works

Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function

Serini, G., Valdembri, D., Zanivan, S. R., Morterra, G., Burkhardt, C., Caccavari, F., Zammataro, L. A., Primo, L., Tamagnone, L., Logan, M. P. O., et al. (2003) · Nature · doi:10.1038/nature01784 · Cited by 575 · see citing works

Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features

Puleo, F., Nicolle, R., Blum, Y., Cros, J., Marisa, L., Demetter, P., Quertinmont, E., Svrcek, M., Elarouci, N., Iovanna, J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.033 · Cited by 563 · see citing works

Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer

Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8719 · Cited by 561 · see citing works

Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis

Wei, D., Le, X., Zheng, L., Wang, L., Frey, J. A., Gao, A. C., Peng, Z., Huang, S., Xiong, H. Q., Abbruzzese, J. L., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206122 · Cited by 558 · see citing works

VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression

Ohm, J. E., Gabrilovich, D. I., Sempowski, G. D., Kisseleva, E. P., Parman, K. S., Nadaf, S., & Carbone, D. P. (2003) · Blood · doi:10.1182/blood-2002-07-1956 · Cited by 539 · see citing works

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

Mace, T. A., Shakya, R., Pitarresi, J. R., Swanson, B. J., McQuinn, C. W., Loftus, S. N., Nordquist, E., Cruz‐Monserrate, Z., Yu, L., Young, G. S., et al. (2016) · Gut · doi:10.1136/gutjnl-2016-311585 · Cited by 535 · see citing works

Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer

Ligorio, M., Sil, S., Malagon-Lopez, J., Nieman, L. T., Misale, S., Pilato, M. D., Ebright, R. Y., Karabacak, M., Kulkarni, A. S., Liu, A., et al. (2018) · Cell · doi:10.1016/j.cell.2019.05.012 · Cited by 534 · see citing works

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma

Murphy, J. E., Wo, J. Y.-L., Ryan, D. P., Jiang, W., Yeap, B. Y., Drapek, L. C., Blaszkowsky, L. S., Kwak, E. L., Allen, J. N., Clark, J. W., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0329 · Cited by 531 · see citing works

Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts

Direkze, N. C., Hodivala-Dilke, K., Jeffery, R., Hunt, T., Poulsom, R., Oukrif, D., Alison, M. R., & Wright, N. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1708 · Cited by 530 · see citing works

Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer

Murphy, J. E., Wo, J. Y.-L., Ryan, D. P., Clark, J. W., Jiang, W., Yeap, B. Y., Drapek, L. C., Ly, L., Baglini, C. V., Blaszkowsky, L. S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0892 · Cited by 525 · see citing works

Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer

Bailey, J. M., Swanson, B. J., Hamada, T., Eggers, J. P., Singh, P. K., Caffrey, T. C., Ouellette, M. M., & Hollingsworth, M. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0291 · Cited by 520 · see citing works

Anatomic Demarcation by Positional Variation in Fibroblast Gene Expression Programs

Rinn, J. L., Bondre, C., Gladstone, H. B., Brown, P. O., & Chang, H. Y. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020119 · Cited by 505 · see citing works

Stromal response to Hedgehog signaling restrains pancreatic cancer progression

Lee, J. J., Perera, R. M., Wang, H., Wu, D.-C., Liu, X. S., Han, S., Fitamant, J., Jones, P. D., Ghanta, K. S., Kawano, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411679111 · Cited by 502 · see citing works

Fibroblast heterogeneity: implications for human disease

Lynch, M. D., & Watt, F. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93555 · Cited by 490 · see citing works

Indexed Pain Journals

(U.S.), N. L. O. M. (2008) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360280801989377 · Cited by 474 · see citing works

Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

Kindler, H. L., Friberg, G. R., Singh, D. A., Locker, G. Y., Nattam, S. R., Kozloff, M. F., Taber, D. A., Karrison, T. G., Dachman, A. H., Stadler, W. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9661 · Cited by 460 · see citing works

Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring

Shi, Y., Gao, W., Lytle, N. K., Huang, P., Yuan, X., Dann, A. M., Ridinger-Saison, M., DelGiorno, K. E., Antal, C. E., Liang, G., et al. (2019) · Nature · doi:10.1038/s41586-019-1130-6 · Cited by 431 · see citing works

Retinoic Acid–Induced Pancreatic Stellate Cell Quiescence Reduces Paracrine Wnt–β-Catenin Signaling to Slow Tumor Progression

Froeling, F. E. M., Feig, C., Chelala, C., Dobson, R., Mein, C. A., Tuveson, D. A., Clevers, H. C., Hart, I. R., & Kocher, H. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.047 · Cited by 421 · see citing works

Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions

Olivares, O., Mayers, J. R., Gouirand, V., Torrence, M. E., Gicquel, T., Borge, L., Lac, S., Roques, J., Lavaut, M.-N., Berthezène, P., et al. (2017) · Nature Communications · doi:10.1038/ncomms16031 · Cited by 413 · see citing works

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

Kindler, H. L., Ioka, T., Richel, D. J., Bennouna, J., Letourneau, R., Okusaka, T., Funakoshi, A., Furuse, J., Park, Y. S., Ohkawa, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70004-3 · Cited by 402 · see citing works

Hepatocytes direct the formation of a pro-metastatic niche in the liver

Lee, J. W., Stone, M. L., Porrett, P. M., Thomas, S. K., Komar, C. A., Li, J. H., Delman, D., Graham, K., Gladney, W. L., Hua, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1004-y · Cited by 402 · see citing works

Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression

Bernard, V., Semaan, A., Huang, J. H., Lucas, F. A. S., Mulu, F. C., Stephens, B. M., Guerrero, P. A., Huang, Y., Zhao, J., Kamyabi, N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1955 · Cited by 387 · see citing works

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation

Tape, C. J., Ling, S., Dimitriadi, M., McMahon, K. M., Worboys, J. D., Leong, H. S., Norrie, I. C., Miller, C. J., Poulogiannis, G., Lauffenburger, D. A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.029 · Cited by 369 · see citing works

Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity

Flint, T. R., Janowitz, T., Connell, C. M., Roberts, E. W., Denton, A. E., Coll, A. P., Jodrell, D. I., & Fearon, D. T. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.010 · Cited by 367 · see citing works

The erbB3 gene product is a receptor for heregulin.

Carraway, K. L., Sliwkowski, M. X., Akita, R., Platko, J. V., Guy, P. M., Nuijens, A., Diamonti, A. J., Vandlen, R. L., Cantley, L. C., & Cerione, R. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36789-3 · Cited by 362 · see citing works

Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.

Iyer, S. N., Gurujeyalakshmi, G., & Giri, S. N. (1999) · PubMed · Cited by 358 · see citing works

Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.

Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352 · see citing works

Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313

Ramanathan, R. K., McDonough, S. L., Philip, P. A., Hingorani, S. R., Lacy, J., Kortmansky, J. S., Thumar, J., Chiorean, E. G., Shields, A. F., Behl, D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01295 · Cited by 336 · see citing works

Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors

Davidson, S. M., Jonas, O., Keibler, M. A., Hou, H. W., Luengo, A., Mayers, J. R., Wyckoff, J., Del Rosario, A. M., Whitman, M., Chin, C. R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4256 · Cited by 331 · see citing works

Type I Collagen Promotes the Malignant Phenotype of Pancreatic Ductal Adenocarcinoma

Armstrong, T., Packham, G., Murphy, L. B., Bateman, A. C., Conti, J. A., Fine, D. R., Johnson, C., Benyon, R. C., & Iredale, J. P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0825 · Cited by 317 · see citing works

Prognostic significance of angiogenesis in human pancreatic cancer

Ikeda, N., Adachi, M., Taki, T., Huang, C., Hashida, H., Takabayashi, A., Sho, M., Nakajima, Y., Kanehiro, H., Hisanaga, M., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690248 · Cited by 315 · see citing works

Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium

Griffioen, A. W., Damen, C. A., Blijham, G. H., & Groenewegen, G. (1996) · Blood · doi:10.1182/blood.v88.2.667.bloodjournal882667 · Cited by 306 · see citing works

Rho‐associated kinases in tumorigenesis: re‐considering ROCK inhibition for cancer therapy

Rath, N., & Olson, M. F. (2012) · EMBO Reports · doi:10.1038/embor.2012.127 · Cited by 304 · see citing works

Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution

Hosein, A. N., Huang, H., Wang, Z., Parmar, K., Du, W., Huang, J., Maitra, A., Olson, E., Verma, U., & Brekken, R. A. (2019) · JCI Insight · doi:10.1172/jci.insight.129212 · Cited by 302 · see citing works

Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models

Thompson, C. B., Shepard, H. M., O'Connor, P. M., Kadhim, S., Jiang, P., Osgood, R. J., Bookbinder, L. H., Li, X., Sugarman, B. J., Connor, R. J., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0470 · Cited by 298 · see citing works

Regulation of Human Macrophage M1–M2 Polarization Balance by Hypoxia and the Triggering Receptor Expressed on Myeloid Cells-1

Raggi, F., Pelassa, S., Pierobon, D., Penco, F., Gattorno, M., Novelli, F., Eva, A., Varesio, L., Giovarelli, M., & Bosco, M. C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01097 · Cited by 282 · see citing works

ATRA mechanically reprograms pancreatic stellate cells to suppress matrix remodelling and inhibit cancer cell invasion

Chronopoulos, A., Robinson, B. K., Sarper, M., Cortés, E., Auernheimer, V., Lachowski, D., Attwood, S. J., García, R., Ghassemi, S., Fabry, B., et al. (2016) · Nature Communications · doi:10.1038/ncomms12630 · Cited by 275 · see citing works

Collagen I–mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1

Shintani, Y., Fukumoto, Y., Chaika, N. V., Svoboda, R. A., Wheelock, M. J., & Johnson, K. R. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200708137 · Cited by 268 · see citing works

Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression.

Itakura, J., Ishiwata, T., Friess, H., Fujii, H., Matsumoto, Y., Büchler, M. W., & Korc, M. (1997) · PubMed · Cited by 268 · see citing works

Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis

Vennin, C., Chin, V. T., Warren, S. C., Lucas, M. C., Herrmann, D., Magenau, A., Mélénec, P., Walters, S. N., del Monte‐Nieto, G., Conway, J. R. W., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai8504 · Cited by 264 · see citing works

Upholding a role for EMT in pancreatic cancer metastasis

Aiello, N. M., Brabletz, T., Kang, Y., Nieto, M. A., Weinberg, R. A., & Stanger, B. Z. (2017) · Nature · doi:10.1038/nature22963 · Cited by 260 · see citing works

Retinoic Acid Receptor Antagonists Inhibit miR-10a Expression and Block Metastatic Behavior of Pancreatic Cancer

Weiß, F. U., Marques, I. J., Woltering, J. M., Vlecken, D. H. W., Aghdassi, A. A., Partecke, L. I., Heidecke, C.-D., Lerch, M. M., & Bagowski, C. P. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.065 · Cited by 258 · see citing works

Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors

Ireland, L., Santos, A., Ahmed, M. S., Rainer, C., Nielsen, S. R., Quaranta, V., Weyer-Czernilofsky, U., Engle, D. D., Pérez-Mancera, P. A., Coupland, S. E., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1201 · Cited by 241 · see citing works

Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment

Stokes, J. B., Adair, S. J., Slack‐Davis, J. K., Walters, D. M., Tilghman, R. W., Hershey, E. D., Lowrey, B. T., Thomas, K. S., Bouton, A. H., Hwang, R. F., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0261 · Cited by 233 · see citing works

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer

Gonçalvès, A., Gilabert, M., François, É., Dahan, L., Perrier, H., Lamy, R., Ré, D., Largillier, R., Gasmi, M., Tchiknavorian, X., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds135 · Cited by 224 · see citing works

A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma

Ko, A. H., LoConte, N. K., Tempero, M. A., Walker, E. J., Kelley, R. K., Lewis, S., Chang, W., Kantoff, E., Vannier, M. W., Catenacci, D. V. T., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000458 · Cited by 223 · see citing works

Designing Liposomes To Suppress Extracellular Matrix Expression To Enhance Drug Penetration and Pancreatic Tumor Therapy

Ji, T., Lang, J., Wang, J., Cai, R., Zhang, Y., Qi, F., Zhang, L., Zhao, X. L., Wu, W., Hao, J., et al. (2017) · ACS Nano · doi:10.1021/acsnano.7b01026 · Cited by 222 · see citing works

Collagen I Promotes Metastasis in Pancreatic Cancer by Activating c-Jun NH2-Terminal Kinase 1 and Up-regulating N-Cadherin Expression

Shintani, Y., Hollingsworth, M. A., Wheelock, M. J., & Johnson, K. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2322 · Cited by 221 · see citing works

Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models

Maione, F., Molla, F., Meda, C., Latini, R., Zentilin, L., Giacca, M., Seano, G., Serini, G., Bussolino, F., & Giraudo, E. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36308 · Cited by 218 · see citing works

Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer

Roland, C. L., Lynn, K. D., Toombs, J. E., Dineen, S. P., Udugamasooriya, D. G., & Brekken, R. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007669 · Cited by 210 · see citing works

Compression of Pancreatic Tumor Blood Vessels by Hyaluronan Is Caused by Solid Stress and Not Interstitial Fluid Pressure

Chauhan, V. P., Boucher, Y., Ferrone, C. R., Roberge, S., Martin, J. D., Stylianopoulos, T., Bardeesy, N. M., DePinho, R. A., Padera, T. P., Munn, L. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.003 · Cited by 205 · see citing works

Hypoxia-Inducible Factor 1 Regulates Vascular Endothelial Growth Factor Expression in Human Pancreatic Cancer

Büchler, P., Reber, H. A., Büchler, M. C., Shrinkante, S., Büchler, M. W., Frieß, H., Semenza, G. L., & Hines, O. J. (2003) · Pancreas · doi:10.1097/00006676-200301000-00010 · Cited by 204 · see citing works

Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts

Nicolle, R., Blum, Y., Marisa, L., Loncle, C., Gayet, O., Moutardier, V., Turrini, O., Giovannini, M. F., Bian, B., Bigonnet, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.003 · Cited by 199 · see citing works

GM-CSF Mediates Mesenchymal–Epithelial Cross-talk in Pancreatic Cancer

Waghray, M., Yalamanchili, M., Dziubinski, M. L., Zeinali, M., Erkkinen, M., Yang, H., Schradle, K. A., Urs, S., di Magliano, M. P., Welling, T. H., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0947 · Cited by 197 · see citing works

Tumor–Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer

Zhang, D., Li, L., Jiang, H., Li, Q., Wang‐Gillam, A., Yu, J., Head, R., Liu, J., Ruzinova, M. B., & Lim, K. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1366 · Cited by 192 · see citing works

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

Rougier, P. R., Riess, H. B., Manges, R., Karásek, P., Humblet, Y., Barone, C., Santoro, A., Assadourian, S., Hatteville, L., & Philip, P. A. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.002 · Cited by 184 · see citing works

Effects of Pirfenidone on Procollagen Gene Expression at the Transcriptional Level in Bleomycin Hamster Model of Lung Fibrosis

Iyer, S. N., Gurujeyalakshmi, G., & Giri, S. N. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38125-x · Cited by 179 · see citing works

STAT3 Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer

Nagathihalli, N. S., Castellanos, J. A., Shi, C.-J., Beesetty, Y., Reyzer, M. L., Caprioli, R., Chen, X., Walsh, A., Skala, M., Moses, H., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.058 · Cited by 178 · see citing works

Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors

Djurec, M., Graña‐Castro, O., Lee, A., Troulé, K., Espinet, E., Cabras, L., Navas, C., Blasco, M. T., Martín-Díaz, L., Burdiel, M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717802115 · Cited by 178 · see citing works

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma

Ambrogio, C., Goméz-López, G., Falcone, M., Vidal, A., Nadal, E., Crosetto, N., Blasco, R. B., Fernández-Marcos, P. J., Sánchez‐Céspedes, M., Ren, X., et al. (2016) · Nature Medicine · doi:10.1038/nm.4041 · Cited by 175 · see citing works

Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options

Kabacaoğlu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 175 · see citing works

Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase

DuFort, C. C., DelGiorno, K. E., Carlson, M. A., Osgood, R. J., Zhao, C., Huang, Z., Thompson, C. B., Connor, R. J., Thanos, C. D., Scott Brockenbrough, J., et al. (2016) · Biophysical Journal · doi:10.1016/j.bpj.2016.03.040 · Cited by 171 · see citing works

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

Fuchs, C. S., Azevedo, S. J., Okusaka, T., Laethem, J. V., Lipton, L. R., Riess, H. B., Szczylik, C. A., Moore, M. J., Peeters, M., Bodoky, G., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv027 · Cited by 168 · see citing works

Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer

Ludwig, K. F., Du, W., Sorrelle, N. B., Wnuk-Lipińska, K., Topalovski, M., Toombs, J. E., Cruz, V. H., Yabuuchi, S., Rajeshkumar, N. V., Maitra, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1973 · Cited by 159 · see citing works

Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop

Öhlund, D., Franklin, O., Lundberg, E., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-154 · Cited by 153 · see citing works

NFκB in Pancreatic Stellate Cells Reduces Infiltration of Tumors by Cytotoxic T Cells and Killing of Cancer Cells, via Up-regulation of CXCL12

Garg, B., Giri, B., Modi, S., Sethi, V., Castro, I., Umland, O., Ban, Y. J., Lavania, S., Dawra, R. K., Banerjee, S., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.05.051 · Cited by 152 · see citing works

Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer.

(2003) · PubMed · Cited by 138 · see citing works

Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer

Takeuchi, S., Baghdadi, M., Tsuchikawa, T., Wada, H., Nakamura, T., Abe, H., Nakanishi, S., Usui, Y., Higuchi, K., Takahashi, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2921 · Cited by 138 · see citing works

α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study

Sinn, M., Denkert, C., Striefler, J. K., Pelzer, U., Stieler, J., Bahra, M., Lohneis, P., Dörken, B., Oettle, H., Riess, H. B., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.495 · Cited by 138 · see citing works

Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature

Gilles, M.-E., Maione, F., Cossutta, M., Carpentier, G., Caruana, L., Maria, S. D., Houppe, C., Destouches, D., Shchors, K., Prochasson, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0300 · Cited by 138 · see citing works

Anti‐stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma

Carapuça, E., Gemenetzidis, E., Feig, C., Bapiro, T. E., Williams, M. D., Wilson, A. S., Delvecchio, F. R., Arumugam, P., Grose, R. P., Lemoine, N. R., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4727 · Cited by 135 · see citing works

ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth

Rath, N., Morton, J. P., Julian, L., Helbig, L., Kadir, S. R., McGhee, E. J., Anderson, K. I., Kalna, G., Mullin, M., Pinho, A. V., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606743 · Cited by 125 · see citing works

HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).

Tempero, M. A., Cutsem, E. V., Sigal, D. S., Oh, D., Fazio, N., Macarulla, T. M., Hitre, E., Hammel, P. R., Hendifar, A. E., Bates, S. E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.638 · Cited by 125 · see citing works

Vascular Endothelial Growth Factor-Trap Suppresses Tumorigenicity of Multiple Pancreatic Cancer Cell Lines

Fukasawa, M., & Korc, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0820 · Cited by 122 · see citing works

Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer

Öhlund, D., Lundin, C., Ardnor, B., Öman, M., Naredi, P. L. J., & Sund, M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605107 · Cited by 120 · see citing works

Inhibition of discoidin domain Receptor 1 reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma

Aguilera, K. Y., Huang, H., Du, W., Hagopian, M. M., Wang, Z., Hinz, S., Hwang, T. H., Wang, H., Fleming, J. B., Castrillon, D. H., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0834 · Cited by 118 · see citing works

Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells

Nagathihalli, N. S., Castellanos, J. A., VanSaun, M. N., Dai, X., Ambrose, M., Guo, Q., Xiong, Y., & Merchant, N. B. (2016) · Oncotarget · doi:10.18632/oncotarget.11786 · Cited by 117 · see citing works

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

Hurwitz, H. I., Cutsem, E. V., Bendell, J. C., Hidalgo, M. M., Li, C., Salvo, M. G., Macarulla, T. M., Sahai, V., Sama, A. R., Greeno, E. W., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0580-2 · Cited by 113 · see citing works

IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma

Long, K. B., Tooker, G. M., Tooker, E., Luque, S. L., Lee, J. W., Pan, X., & Beatty, G. L. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0899 · Cited by 112 · see citing works

Inhibition of IL‐6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer

Goumas, F. A., Holmer, R., Egberts, J., Gontarewicz, A., Heneweer, C., Geisen, U., Hauser, C., Mende, M., Legler, K., Röcken, C., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29445 · Cited by 111 · see citing works

Knockdown of the β 1 integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis

Grzesiak, J. J., Cao, H. S. T., Burton, D. W., Kaushal, S., Vargas, F., Clopton, P., Snyder, C. S., Deftos, L. J., Hoffman, R. M., & Bouvet, M. (2011) · International Journal of Cancer · doi:10.1002/ijc.25942 · Cited by 104 · see citing works

The Molecular Basis of Pancreatic Fibrosis

Binkley, C. E., Zhang, L., Greenson, J. K., Giordano, T. J., Kuick, R. D., Misek, D., Hanash, S., Logsdon, C. D., & Simeone, D. M. (2004) · Pancreas · doi:10.1097/00006676-200411000-00003 · Cited by 102 · see citing works

Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma

Aguilera, K. Y., Rivera, L. B., Hur, H., Carbon, J. G., Toombs, J. E., Goldstein, C. D., Dellinger, M. T., Castrillon, D. H., & Brekken, R. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2800 · Cited by 100 · see citing works

Immunohistochemical expression of extracellular matrix proteins and adhesion molecules in pancreatic carcinoma.

Linder, S., Castaños‐Vélez, E., von Rosen, A., et al. (2002) · PubMed · Cited by 99 · see citing works

Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)

Philip, P. A., Goldman, B. H., Ramanathan, R. K., Lenz, H., Lowy, A. M., Whitehead, R. P., Wakatsuki, T., Iqbal, S., Gaur, R., Benedetti, J., et al. (2014) · Cancer · doi:10.1002/cncr.28744 · Cited by 94 · see citing works

Pancreatic cancer cell-derived vascular endothelial growth factor is biologically activein vitro and enhances tumorigenicityin vivo

Luo, J., Guo, P., Matsuda, K., Truong, N., Lee, A., Chun, C. L., Cheng, S., & Korc, M. (2001) · International Journal of Cancer · doi:10.1002/ijc.1202 · Cited by 93 · see citing works

Anti-VEGF Treatment–Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype

Carbone, C., Moccia, T., Zhu, C., Paradiso, G., Budillon, A., Chiao, P. J., Abbruzzese, J. L., & Melisi, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1185 · Cited by 92 · see citing works

Pancreatic stellate cells regulate blood vessel density in the stroma of pancreatic ductal adenocarcinoma

Maggio, F. D., Arumugam, P., Delvecchio, F. R., et al. (2016) · Pancreatology · doi:10.1016/j.pan.2016.05.393 · Cited by 87 · see citing works

Targeting TGFβR2‐mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer

Huang, H., Zhang, Y., Gallegos, V., Sorrelle, N., Zaid, M. M., Toombs, J., Du, W., Wright, S., Hagopian, M., Wang, Z., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910515 · Cited by 87 · see citing works

Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts.

Bockhorn, M., Tsuzuki, Y., Xu, L., et al. (2003) · PubMed · Cited by 83 · see citing works

ATRA modulates mechanical activation of TGF-β by pancreatic stellate cells

Sarper, M., Cortés, E., Lieberthal, T. J., & Hernández, A. E. D. R. (2016) · Scientific Reports · doi:10.1038/srep27639 · Cited by 80 · see citing works

Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolutionPreprint

Hosein, A. N., Huang, H., Wang, Z., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/539874 · Cited by 79 · see citing works

Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer

Rucki, A. A., Foley, K., Zhang, P., Xiao, Q., Kleponis, J., Wu, A. A., Sharma, R. B., Mo, G., Liu, A., Eyk, J. E. V., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1383 · Cited by 77 · see citing works

Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis

Galluzzo, M., Pennacchietti, S., Rosano, S., Comoglio, P. M., & Michieli, P. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36579 · Cited by 73 · see citing works

Up-regulation of N-cadherin by Collagen I-activated Discoidin Domain Receptor 1 in Pancreatic Cancer Requires the Adaptor Molecule Shc1

Huang, H., Svoboda, R. A., Lazenby, A. J., Saowapa, J., Chaika, N. V., Ding, K., Wheelock, M. J., & Johnson, K. R. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.740605 · Cited by 68 · see citing works

Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric carcinoma

Hur, H., Ham, I., Lee, D., Jin, H., Aguilera, K. Y., Oh, H. J., Han, S., Kwon, J. E., Kim, Y.-B., Ding, K., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3051-9 · Cited by 68 · see citing works

Hydration Dynamics of Hyaluronan and Dextran

Hunger, J., Bernecker, A., Bakker, H. J., Bonn, M., & Richter, R. P. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.05.028 · Cited by 65 · see citing works

VDR signaling inhibits cancer-associated-fibroblasts’ release of exosomal miR-10a-5p and limits their supportive effects on pancreatic cancer cells

Kong, F., Li, L., Wang, G., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-316627 · Cited by 65 · see citing works

A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent

Gioelli, N., Maione, F., Camillo, C., Ghitti, M., Valdembri, D., Morello, N., Darche, M., Zentilin, L., Cagnoni, G., Qiu, Y., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4807 · Cited by 57 · see citing works

Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)

Kundranda, M. N., Gracián, A. C., Zafar, S. F., Meiri, E., Bendell, J. C., Algül, H., Rivera, F., Ahn, E. R., Watkins, D. J., Pelzer, U., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.09.004 · Cited by 53 · see citing works

Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern

Kim, H. W., Lee, J.-C., Paik, K.-H., Kang, J., Kim, J., & Hwang, J.-H. (2017) · Medicine · doi:10.1097/md.0000000000005926 · Cited by 52 · see citing works

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

Abdel‐Wahab, R., Varadhachary, G. R., Bhosale, P., Wang, X., Fogelman, D. R., Shroff, R. T., Overman, M. J., Wolff, R. A., & Javle, M. M. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0616-2 · Cited by 50 · see citing works

Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer

Zhong, Y., Macgregor‐Das, A. M., Saunders, T., Whittle, M. C., Makohon-Moore, A. P., Kohutek, Z. A., Poling, J., Herbst, B. T., Javier, B. M., Cope, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1615 · Cited by 48 · see citing works

25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance)

Loon, K. V., Owzar, K., Jiang, C., Kindler, H. L., Mulcahy, M. F., Niedzwiecki, D., O'Reilly, E. M., Fuchs, C. S., Innocenti, F., & Venook, A. P. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju185 · Cited by 38 · see citing works

The Past, Present, and Future of Pancreatic Cancer Clinical Trials

Matrisian, L. M., & Berlin, J. D. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159117 · Cited by 37 · see citing works

First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti–CSF-1 Receptor (cabiralizumab) Plus Anti–PD-1 (nivolumab), in Patients With Advanced Solid Tumors

Wainberg, Z. A., Piha-Paul, S. A., Luke, J., Kim, E. J., Thompson, J. A., Britten, C. D., Johnson, J. M., Pfanzelter, N., Gordon, M. S., Rasco, D. W., et al. (2018) · doi:10.13140/rg.2.2.28962.53443 · Cited by 37 · see citing works

Molecular envoys pave the way for pancreatic cancer to invade the liver

Maitra, A. (2019) · Nature · doi:10.1038/d41586-019-00710-z · Cited by 36 · see citing works

Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.

Wang‐Gillam, A., Lockhart, A. C., Tan, B. R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.2561 · Cited by 30 · see citing works

Low Stromal Area and High Stromal Microvessel Density Predict Poor Prognosis in Pancreatic Cancer

Nishida, T., Yoshitomi, H., Takano, S., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000499 · Cited by 27 · see citing works

Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.

Wang‐Gillam, A., Lockhart, A. C., Tan, B. R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.380 · Cited by 25 · see citing works

A phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC).

Borazanci, E. H., Jameson, G., Borad, M. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.358 · Cited by 21 · see citing works

Starving Tumors of Their Lifeblood

Ezzell, C. (1998) · Scientific American · doi:10.1038/scientificamerican1098-33 · Cited by 19 · see citing works

Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer

Zhang, Y., Kirane, A., Huang, H., Sorrelle, N. B., Burrows, F. J., Dellinger, M. T., & Brekken, R. A. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0427 · Cited by 18 · see citing works

A phase II pilot trial of nivolumab + albumin bound paclitaxel + paricalcitol + cisplatin + gemcitabine (NAPPCG) in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma.

Borazanci, E. H., Jameson, G., Borad, M. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.tps511 · Cited by 16 · see citing works

Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial

Infante, J. R., Arkenau, H., Bendell, J. C., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23625 · Cited by 14 · see citing works

A Multi-Center Phase IIA Trial to Assess the Safety and Efficacy of BL-8040 (a CXCR4 Inhibitor) in Combination with Pembrolizumab and Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma (PDAC)

Hidalgo, M. M., Semenisty, V., Bockorny, B., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz451 · Cited by 14 · see citing works

Histological Advantages of the Tumor Graft

Akashi, Y., Oda, T., Ohara, Y., et al. (2013) · Pancreas · doi:10.1097/mpa.0b013e318296f866 · Cited by 11 · see citing works

Multicenter, Open-Label, Phase I/II Study of Tocilizumab, an Anti–Interleukin-6 Receptor Monoclonal Antibody, Combined with Gemcitabine in Patients with Advanced Pancreatic Cancer

Mitsunaga, S., Okusaka, T., Ikeda, M., Ozaka, M., Ohkawa, S., Ioka, T., Shimura, T., Sato, K., Terao, K., Ochiai, A., et al. (2017) · Journal of Medical Diagnostic Methods · doi:10.4172/2168-9784.1000234 · Cited by 7 · see citing works

Association of single nucleotide polymorphisms (SNPs) in CYP17A1 and SLCO2B1 genes and clinical outcome in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: results of the ABIGENE prospective study.

Borchiellini, D., Mahammedi, H., Viotti, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.6_suppl.358 · Cited by 5 · see citing works

Immune checkpoint molecule expression measured using circulating cell-free RNA isolated from the blood of metastatic prostate cancer patients.

Kollengode, K. A., Grussie, E., Danenberg, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.6_suppl.380 · Cited by 5 · see citing works

STAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer

Kocher, H. M., Basu, B., Froeling, F. E. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz247.027 · Cited by 4 · see citing works

Abstract 1489: Targeting the mitochondrial enzyme proline dehydrogenase with a mechanism-based irreversible inhibitor induces selective mitochondrial stress and enhances breast cancer cell death under hypoxia

Scott, G. K., Frazier, K., Yau, C. S. F., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-1489 · Cited by 2 · see citing works

The effect of prophylactic cranial irradiation (PCI) for young stage III NSCLC patients: Subgroup analyses of the NVALT-11/DLCRG-02 study

Witlox, W. J. A., Ramaekers, B., Groen, H. J. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz067.003 · Cited by 2 · see citing works

Pancreatic cancer: Advances and challenges

Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321 · see citing works

Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer

Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773 · see citing works

Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer

Huang, H., Wang, Z., Zhang, Y., Pradhan, R. N., Ganguly, D., Chandra, R., Murimwa, G., Wright, S., Gu, X., Maddipati, R., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.011 · Cited by 542 · see citing works

Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment

Hwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Reeves, J. W., Mohan, R., Drokhlyansky, E., Van Wittenberghe, N., Ashenberg, O., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01134-8 · Cited by 426 · see citing works

Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer

Wasko, U. N., Jiang, J., Dalton, T. C., Curiel-Garcia, A., Edwards, A. C., Wang, Y., Lee, B., Orlen, M., Tian, S., Stalnecker, C. A., et al. (2024) · Nature · doi:10.1038/s41586-024-07379-z · Cited by 209 · see citing works

Heterogeneity of HSCs in a Mouse Model of NASH

Rosenthal, S. B., Liu, X., Ganguly, S., Dhar, D., Pasillas, M. P., Ricciardelli, E., Li, R. Z., Troutman, T. D., Kisseleva, T., Glass, C. K., et al. (2021) · Hepatology · doi:10.1002/hep.31743 · Cited by 145 · see citing works

Elucidation of tumor-stromal heterogeneity and the ligand-receptor interactome by single-cell transcriptomics in Real-world pancreatic cancer biopsies

Lee, J. J., Bernard, V., Semaan, A., Monberg, M. E., Huang, J., Stephens, B. M., Lin, D., Rajapakshe, K. I., Weston, B. R., Bhutani, M. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3925 · Cited by 128 · see citing works

Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches

Truong, L.-H., & Pauklin, S. (2021) · Cancers · doi:10.3390/cancers13195028 · Cited by 102 · see citing works

Matrix stiffness affects tumor-associated macrophage functional polarization and its potential in tumor therapy

Xiong, J., Xiao, R., Zhao, J., Zhao, Q., Luo, M., Li, F., Zhang, W., & Wu, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04810-3 · Cited by 79 · see citing works

Pre-clinical Models of Metastasis in Pancreatic Cancer

Miquel, M., Zhang, S., & Pilarsky, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.748631 · Cited by 53 · see citing works

Targeting autophagy as a therapeutic strategy against pancreatic cancer

Yamamoto, K., Iwadate, D., Kato, H., Nakai, Y., Tateishi, K., & Fujishiro, M. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01889-1 · Cited by 29 · see citing works

Therapeutic Approaches in Pancreatic Cancer: Recent Updates

Kumar, L., Kumar, S., Sandeep, K., & Patel, S. K. S. (2023) · Biomedicines · doi:10.3390/biomedicines11061611 · Cited by 25 · see citing works

Machine learning analyses of highly-multiplexed immunofluorescence identifies distinct tumor and stromal cell populations in primary pancreatic tumors1

Vance, K., Alitinok, A., Winfree, S., Jensen-Smith, H., Swanson, B. J., Grandgenett, P. M., Klute, K. A., Crichton, D. J., & Hollingsworth, M. A. (2022) · Cancer Biomarkers · doi:10.3233/cbm-210308 · Cited by 14 · see citing works

SRC at the Crossroads of KRAS Inhibitor Resistance: Mechanisms and Therapeutic Opportunities

Tian, H., Zhao, D., Zhou, Z., Kim, A., Huang, H., Lee, Y. J., Qu, Z., Kang, R., Zeh, H. J., Westover, K. D., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2025.218194 · Cited by 7 · see citing works

Spatial multi-omics uncovers an invasive-desmoplastic cellular community with prognostic and therapeutic implications in pancreatic ductal adenocarcinoma

Liang, C.-H., Ye, H., Xu, H., Fang, C., Lian, J.-P., Chen, Y.-Q., Wang, W.-T., & He, B. (2026) · Advanced Biotechnology · doi:10.1007/s44307-026-00141-8

Disrupting the Balance between Tumor Epithelia and Stroma is a Possible Therapeutic Approach for Pancreatic Cancer

Li, X. (2014) · Medical Science Monitor · doi:10.12659/msm.892523 · Cited by 10 · see citing works

Stromal desmoplasia as a possible prognostic indicator in different grades of oral squamous cell carcinoma

Zainab, H., Sultana, A., & Shaimaa (2019) · Journal of Oral and Maxillofacial Pathology · doi:10.4103/jomfp.jomfp_136_19 · Cited by 36 · see citing works

THE PREDICTIVE VALUES OF DESMOPLASTIC FIBROSIS AND THE MATURITY OF CONNECTIVE TISSUE COMPONENT OF PAPILLARY THYROID MICROCARCINOMAS

Yakovtsova, I. I., Ивахно, И. В., Arsenyev, A. V., et al. (2016) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2016.1.01

The stromal compartments in pancreatic cancer: Are there any therapeutic targets?

Lunardi, S., Muschel, R. J., & Brunner, T. B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.09.039 · Cited by 176 · see citing works

Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?

Delma, M. I. (2020) · Cureus · doi:10.7759/cureus.10909